Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis (MG), Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials

    Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis (MG), Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials

    FromAmerican Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)

    Start listeningView podcast show

    Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis (MG), Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials

    FromAmerican Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)

    ratings:
    Length:
    67 minutes
    Released:
    Dec 13, 2022
    Format:
    Podcast episode

    Description

    Elie Naddaf, MD, interviews James Howard, MD, about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis (MG), highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.
    Released:
    Dec 13, 2022
    Format:
    Podcast episode

    Titles in the series (100)

    Hear from a variety of experts on all things neuromuscular & electrodiagnostic medicine. Learn new science, hear expert perspectives, and join the conversation!